Genentech brings ops savvy, pipeline to Roche

Despite its pipeline-enhancing objective, the acquisition of Genentech by Roche is showing a nod by the centenarian drugmaker to the upstart's operations talents. Genentech scientists are stepping into key manufacturing jobs for Roche--global manufacturing chief Pat Yang and North American commercial ops chief Ian Clark are two examples.

Similarly, Genentech operations have fared well in a post-merger manufacturing shake-up.  The Swiss drug giant closed its Palo Alto, CA, facility and cut hundreds of jobs in New Jersey.

By a more common metric, Genentech's generated revenue per employee of $1.2 million in 2008 bests Roche's $528,000, according to Bloomberg.

- here's the article

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)